#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Follicular lymphoma stage I Glioblastoma multiforme Necrotising myositis Ductal adenocarcinoma of pancreas Pulmonary tuberculosis Small cell lung cancer recurrent Follicle centre lymphoma follicular grade I II – III refractory Osteosarcoma metastatic Duchenne muscular dystrophy Polycystic liver disease Primitive neuroectodermal tumour Renal disorder Microscopic polyangiitis Malignant peritoneal neoplasm Neuropathy peripheral More trials…

    Learn about Rare Diseases

    Crigler-Najjar syndrome – Basic Information Krabbe’s disease – Life with Disease Retinoblastoma – Basic Information Mucopolysaccharidosis Biotinidase deficiency Gaucher’s disease type III – Basic Information Metachromatic leukodystrophy – Life with Disease Mucopolysaccharidosis I – Trials in Disease Turner’s syndrome – Basic Information Mantle cell lymphoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mometasone Furoate Ph. Eur. Pyruvic Acid Revumenib Tyra-300-B01 A/(H3N2)-LIKE VIRUS ANTIGEN Gskvx000000009151 Db-1303 Disodium Folinate Vibozilimod Haloperidol Decanoate Vusolimogene Oderparepvec Nvdx3 Ertapenem Sodium Bay 3283142 Sodium Phenylbutyrate Mitazalimab Cemdisiran Fingolimod Hydrochloride Bbp-398 Canis Familiaris (553) More therapies…

    Learn about Your Condition

    Uterine cancer Von Willebrand's disease Metastases to liver Head injury Angelman's syndrome Cardiac failure chronic Papilloma viral infection Aortic valve disease Renal failure Bacteraemia Neck pain Atopic keratoconjunctivitis Intracranial calcification Postoperative wound infection Adenomatous polyposis coli More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Hospital Universitario Mutua Terrassa

Hospital Universitario Mutua Terrassa

Plaza del Dr. Robert 5, Terrassa, 08221, Spain

Want to learn more about this study or check if you can participate? Contact us.

  • Short-Acting Pasireotide Test to Predict Treatment Response in Patients with Acromegaly

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Pasireotide
    Spain

  • Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Linvoseltamab
    • Daratumumab
    France Germany Greece Italy Norway Poland +1

  • A Study of Linvoseltamab Alone and Linvoseltamab with Carfilzomib Compared to Standard Treatment in Adults with Relapsed or Refractory Multiple Myeloma

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Aciclovir
    • Linvoseltamab
    • Carfilzomib
    Austria Belgium Czechia France Germany Greece +4

  • Study on Redasemtide for Adults with Acute Ischemic Stroke Not Eligible for Standard Treatments

    Not yet recruiting

    2 1
    Investigated Drugs:
    • Redasemtide
    Belgium Czechia Denmark Finland France Germany +3

  • Study on Elranatamab and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma After Prior Treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Elranatamab
    • Daratumumab
    • Human Normal Immunoglobulin
    Austria Belgium Czechia Finland France Germany +7

  • A Study of Cabazitaxel and Pelvic Radiation Therapy Combined with Hormone Treatment for Patients with High-Risk Localized Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Cabazitaxel
    Belgium France Spain

  • Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

    Not recruiting

    3 1
    Investigated Drugs:
    • Enasidenib Mesilate
    • Ivosidenib
    Austria Belgium Estonia Finland France Germany +6

  • Study on the Safety of Low-Dose Cytarabine or Azacitidine with Venetoclax and Quizartinib for Acute Myeloid Leukemia in Patients Aged 60+ Ineligible for Standard Chemotherapy

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Quizartinib Dihydrochloride
    • Venetoclax
    Spain

  • Study on AON-D21 for Patients with Severe Community-Acquired Pneumonia in Intensive Care

    Not recruiting

    2 1
    Investigated Drugs:
    • Aon-D21
    Belgium France Germany Spain

  • Study Comparing 7-Day and 14-Day Treatment with Vancomycin, Linezolid, and Daptomycin for Patients with Uncomplicated Enterococcal Blood Infections

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Bacterial infection
    Investigated Drugs:
    • Ampicillin Sodium
    • Daptomycin
    • Piperacillin Sodium
    Spain
Previous Page
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!